Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix (NBTX) has released initial data from a completed Phase 1 dose escalation study evaluating NBTXR3 (JNJ-1900) as a second-line or later therapy for locally advanced non-small cell lung cancer (NSCLC) patients eligible for re-irradiation.

The study, conducted at MD Anderson Cancer Center, demonstrated favorable safety outcomes with no dose-limiting toxicities or Grade 3+ serious adverse events related to NBTXR3. The recommended phase 2 dose was established at 33% of gross tumor volume.

Preliminary survival data from 12 patients showed promising results with:

• 12-month local progression-free survival (LPFS) of 64% (median 18.6 months)
• 12-month overall survival (OS) of 83% (median 30.2 months)

The expansion phase is currently ongoing with 5 out of 12 patients injected to date.

Nanobiotix announced upcoming presentations of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the 2025 European Lung Cancer Conference (ELCC). The first study, presented by Dr. Saumil Gandhi, focuses on safety and early efficacy signals, including updated local PFS, for re-irradiation with JNJ-1900 in patients with unresectable, locoregional recurrent NSCLC.

The second study, presented by Dr. Colette Shen, evaluates safety and injection feasibility of JNJ-1900 in combination with nivolumab or pembrolizumab for treating patients with lung metastases from NSCLC or other solid tumors. Both presentations are scheduled for March 28th, 2025, at 8:00 AM EDT / 1:00 PM CET.

Nanobiotix (NASDAQ: NBTX) has amended its global licensing agreement with Johnson & Johnson's Janssen Pharmaceutica NV, strengthening its financial position through 2026. Key changes include:

- J&J will now cover most costs for the ongoing NANORAY-312 Phase 3 trial
- Overall deal value adjusted from $2.7B to $2.6B
- Potential milestone payments include:

• $1.77B for first programs including head and neck cancer and lung cancer
• $650M for five new potential indications
• $165M for Asian market developments
• $220M per new indication developed by Nanobiotix

The company maintains tiered double-digit royalties (low 10s to low 20s) and extends cash runway to mid-2026. Nanobiotix expects reduced operational cash burn and is exploring additional non-dilutive financing options to extend runway into 2027.

Nanobiotix (NBTX) has issued a standard regulatory filing regarding its voting rights and share capital in compliance with French regulatory requirements. The announcement was made in accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the French Financial Markets Authority regulations.

The company's shares are listed on both Euronext Paris (Compartment B) and Nasdaq under the ticker symbol NBTX. The company's ISIN code is FR0011341205.

Nanobiotix (NBTX) has released its latest voting rights and shares capital update as of January 31, 2025. The company reported 47,426,851 shares outstanding, with 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, dual-listed on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, has announced its participation in two major investor conferences in early 2025.

The company will participate in fireside chats at the following events:

• Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 1pm ET in New York, featuring CFO Bart van Rhijn
• Leerink Global Healthcare Conference on March 12, 2025, at 10:40pm ET in Miami, featuring CEO Laurent Levy and CFO Bart van Rhijn

Both fireside chats will be webcast live through the company's website's Investors section, with replays available after the events.

Nanobiotix announced the dosing of the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating JNJ-1900 (NBTXR3) for treating Stage 3 unresectable non-small cell lung cancer. The study will assess patients receiving standard chemoradiation followed by consolidation durvalumab.

The trial (NCT06667908) is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. JNJ-1900 is a potential first-in-class radioenhancer designed to address unmet needs in radiotherapy patients. This development follows the NANORAY-312 trial path for potential registration in head and neck cancer.

Nanobiotix (NBTX) has released its latest voting rights and shares capital statement as of December 31, 2024. The company reports 47,426,851 shares outstanding, with 49,204,910 theoretical voting rights and 49,182,792 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms: oncology, bioavailability and biodistribution, and disorders of the central nervous system.

Nanobiotix (NBTX) announced a virtual event titled 'Accelerating the Future of Nanotherapeutics' scheduled for December 19, 2024, at 9:00 AM ET / 3:00 PM CET. The event will showcase the company's Curadigm Nanoprimer Platform, a new nanotherapeutic technology designed to enhance intravenously-administered therapeutics.

The presentation will feature CEO Laurent Lévy and Curadigm Head Matthieu Germain, followed by a panel discussion with experts including Margaret A. Liu, a globally recognized authority in gene therapy, vaccines, and immunotherapy. The company confirms its lead program is proceeding as planned while exploring new nanotherapeutic technologies to improve patient treatment outcomes.